ATE292626T1 - Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf) - Google Patents

Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)

Info

Publication number
ATE292626T1
ATE292626T1 AT97907247T AT97907247T ATE292626T1 AT E292626 T1 ATE292626 T1 AT E292626T1 AT 97907247 T AT97907247 T AT 97907247T AT 97907247 T AT97907247 T AT 97907247T AT E292626 T1 ATE292626 T1 AT E292626T1
Authority
AT
Austria
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
production
Prior art date
Application number
AT97907247T
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE292626T1 publication Critical patent/ATE292626T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97907247T 1996-05-03 1997-04-01 Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf) ATE292626T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (1)

Publication Number Publication Date
ATE292626T1 true ATE292626T1 (de) 2005-04-15

Family

ID=21779401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907247T ATE292626T1 (de) 1996-05-03 1997-04-01 Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)

Country Status (41)

Country Link
US (2) US6211222B1 (de)
EP (1) EP0912521B1 (de)
JP (1) JP3148254B2 (de)
KR (1) KR100339935B1 (de)
CN (2) CN1112359C (de)
AP (4) AP2001002304A0 (de)
AR (1) AR006906A1 (de)
AT (1) ATE292626T1 (de)
AU (1) AU725576B2 (de)
BG (1) BG64211B1 (de)
BR (1) BR9709051A (de)
CA (2) CA2252982C (de)
CO (1) CO4650038A1 (de)
CZ (1) CZ292825B6 (de)
DE (1) DE69732966T2 (de)
DZ (1) DZ2217A1 (de)
EA (1) EA002272B1 (de)
ES (1) ES2238079T3 (de)
GT (1) GT199700043A (de)
HN (1) HN1997000046A (de)
HR (1) HRP970227B1 (de)
HU (1) HUP9902459A3 (de)
ID (1) ID16856A (de)
IL (2) IL152083A0 (de)
IS (1) IS4871A (de)
MA (1) MA24158A1 (de)
MY (1) MY132499A (de)
NO (1) NO312959B1 (de)
NZ (1) NZ332240A (de)
OA (1) OA10904A (de)
PE (1) PE64598A1 (de)
PL (1) PL329836A1 (de)
SK (1) SK148298A3 (de)
TN (1) TNSN97070A1 (de)
TR (1) TR199802202T2 (de)
TW (1) TW449585B (de)
UA (1) UA65536C2 (de)
UY (1) UY24532A1 (de)
WO (1) WO1997042174A1 (de)
YU (1) YU16397A (de)
ZA (1) ZA973804B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
ES2172882T3 (es) * 1997-05-08 2002-10-01 Pfizer Prod Inc Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.
TR200001234T2 (tr) * 1997-11-04 2000-08-21 Pfizer Products Inc. Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi.
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
CN1281441A (zh) * 1997-11-04 2001-01-24 辉瑞产品公司 以在pde4抑制剂中的儿茶酚的吲唑生物等排物置换为基础的治疗活性化合物
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6303782B1 (en) * 1999-04-20 2001-10-16 Pfizer Inc Process for preparing benzylnitriles
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
DE60018470T2 (de) * 1999-12-23 2006-02-16 Icos Corp., Bothell Cyclische amp spezifische phosphodiesterase inhibitoren
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
PT1908463E (pt) 2001-12-14 2011-12-19 Merck Serono Sa Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021016B1 (de) * 2006-04-21 2016-01-06 Janssen Biotech, Inc. Cxcl-13-antagonisten und tnf-alpha-antagonisten zur verwendung in einer kombinationstherapie
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AU2018360766B2 (en) 2017-11-06 2024-09-19 Rapt Therapeutics, Inc. Anticancer agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (de) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
HU217661B (hu) * 1992-03-09 2000-03-28 Zeneca Ltd. Aril-indazol-származékok, eljárás az előállításukra és herbicidként történő alkalmazásuk
FI944549L (fi) * 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
PL319758A1 (en) * 1994-10-20 1997-08-18 Pfizer Bicyclic tetrahydropyrasole pyridines and their application as medicines
KR970707243A (ko) * 1994-10-21 1997-12-01 헤이만, 로버트 엘 금속제품에 대한 내식성 완충 시스템(corrosion resistant buffer system for metal products)
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
ES2172882T3 (es) * 1997-05-08 2002-10-01 Pfizer Prod Inc Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.

Also Published As

Publication number Publication date
US6127398A (en) 2000-10-03
PL329836A1 (en) 1999-04-12
JPH11508284A (ja) 1999-07-21
MY132499A (en) 2007-10-31
HUP9902459A2 (hu) 1999-11-29
CA2389918A1 (en) 1997-11-13
JP3148254B2 (ja) 2001-03-19
CO4650038A1 (es) 1998-09-03
AP2001002304A0 (en) 2001-12-31
CN1112359C (zh) 2003-06-25
HK1019443A1 (en) 2000-02-11
AR006906A1 (es) 1999-09-29
CZ292825B6 (cs) 2003-12-17
OA10904A (en) 2001-10-11
GT199700043A (es) 1998-10-02
TW449585B (en) 2001-08-11
NO985095L (no) 1998-12-29
BR9709051A (pt) 1999-08-03
AU1937397A (en) 1997-11-26
HRP970227A2 (en) 2000-12-31
ID16856A (id) 1997-11-13
KR20000010751A (ko) 2000-02-25
NZ332240A (en) 2000-07-28
NO312959B1 (no) 2002-07-22
KR100339935B1 (ko) 2002-07-18
AP9700975A0 (en) 1997-07-31
EP0912521B1 (de) 2005-04-06
AP0102304A0 (en) 1997-11-03
AP1147A (en) 2003-02-25
UY24532A1 (es) 2000-09-29
DE69732966T2 (de) 2005-09-08
AU725576B2 (en) 2000-10-12
AP1146A (en) 2003-02-25
HN1997000046A (es) 1997-06-26
NO985095D0 (no) 1998-11-02
DE69732966D1 (de) 2005-05-12
CA2252982C (en) 2002-10-08
HUP9902459A3 (en) 2001-10-29
PE64598A1 (es) 1998-10-26
EA199800882A1 (ru) 1999-06-24
YU16397A (sh) 1999-12-27
BG102946A (en) 1999-11-30
CZ349298A3 (cs) 1999-09-15
EP0912521A1 (de) 1999-05-06
AP2001002294A0 (en) 2001-12-31
IS4871A (is) 1998-10-16
WO1997042174A1 (en) 1997-11-13
UA65536C2 (en) 2004-04-15
IL152083A0 (en) 2003-05-29
CN1217714A (zh) 1999-05-26
SK148298A3 (en) 2000-02-14
TR199802202T2 (xx) 1999-02-22
TNSN97070A1 (fr) 2005-03-15
IL126547A (en) 2003-03-12
CA2252982A1 (en) 1997-11-13
MA24158A1 (fr) 1997-12-31
HRP970227B1 (en) 2002-06-30
CN1422849A (zh) 2003-06-11
BG64211B1 (bg) 2004-05-31
ES2238079T3 (es) 2005-08-16
EA002272B1 (ru) 2002-02-28
DZ2217A1 (fr) 2002-12-03
ZA973804B (en) 1998-11-02
IL126547A0 (en) 1999-08-17
US6211222B1 (en) 2001-04-03

Similar Documents

Publication Publication Date Title
DE69732966D1 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)
ATE244713T1 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)
IL128642A0 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
DE59913617D1 (de) Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
ATE268761T1 (de) Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
DE59703869D1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
CA2233975A1 (en) Succinimide and maleimide cytokine inhibitors
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
AU3102697A (en) Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
DE69840519D1 (de) Heteroaryl-hexansäureamid-derivate, ihre herstellung und ihre verwendung als selektive inhibitoren der bindung von mip-1-alpha an seinen ccr1 rezeptor
AU3261293A (en) Heterocyclic sulfonamide derivatives as antagonists of paf and angiotensin II
HU9503089D0 (en) Use of indole derivatives as 5ht1 antagonists
DE69708629D1 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
ATE89820T1 (de) 4-amino-3-acylchinolin-derivate, und ihre verwendung als inhibitioren der magensekretion.
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties